Less restrictive enrollment criteria warranted for MDS clinical trialsJune 8, 2021Myelodysplastic Syndrome
T-cell inhibition by PD-L1-expressing stem cells may play a role in MDS developmentJune 8, 2021Myelodysplastic Syndrome
Increased cumulative exposure to melphalan in multiple myeloma patients increases MDS riskJune 8, 2021Myelodysplastic Syndrome
MDS: Adolescents and young adults have a favorable survival with allo-HSCTJune 8, 2021Myelodysplastic Syndrome
MDS del5q: Could DNA methylation patterns predict response to lenalidomide?June 8, 2021Myelodysplastic Syndrome
TP53-mutated MDS: Eprenetapopt plus azacitidine is safe and favorableJune 8, 2021Myelodysplastic Syndrome
Decitabine with microtransplantation shows promise in intermediate- or high-risk MDSMay 3, 2021Myelodysplastic Syndrome
Low-risk MDS: Higher dose of hypomethylating agents promotes transfusion independenceMay 3, 2021Myelodysplastic Syndrome
MDS: No survival benefit with hypomethylating agents bridging therapy before allo-HSCTMay 3, 2021Myelodysplastic Syndrome
Risk of organizing pneumonia high in MDS patients with der(1;7)(q10; p10) abnormalityMay 3, 2021Myelodysplastic Syndrome
Quizartinib-based combinations safe and effective for untreated MDSMay 3, 2021Myelodysplastic Syndrome
Stanozolol: An effective alternative treatment for lower-risk MDS after epoetin alfa failureMay 3, 2021Myelodysplastic Syndrome
